Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Michael Palese"'
Autor:
Ketan K. Badani, Michael Palese, Aaron M. Fischman, Colton Welch, Reza Mehrazin, John J. Griffith, Zeynep Gul
Publikováno v:
Urology. 125:118-122
Objective To evaluate outcomes after focal ablative therapy for renal cell carcinoma (RCC) in transplant allograft kidneys. Methods After institutional review board approval, patients with a history of RCC in a transplanted allograft kidney who under
Autor:
Benjamin A. Gartrell, William Oh, Juan P. Wisnivesky, James Godbold, Simon J. Hall, Erin Moshier, Matthew D. Galsky, Michael Palese, Guru Sonpavde, Max Kates, Che-Kai Tsao, Alexander C. Small
Publikováno v:
World Journal of Urology. 31:1535-1539
Two randomized trials published in 2001 provided level 1 evidence for the use of cytoreductive nephrectomy (CyNx) for the treatment of metastatic renal cell carcinoma (mRCC). However, the regulatory approval of vascular endothelial growth factor tyro
Autor:
Che-Kai Tsao, James Godbold, Michael Palese, Alexander C. Small, William Oh, Guru Sonpavde, Matthew D. Galsky, Simon J. Hall, Benjamin A. Gartrell, Juan P. Wisnivesky, Erin Moshier
Publikováno v:
Clinical Genitourinary Cancer. 10:159-163
Two randomized trials published in 2001 established CyNx for patients with metastatic renal carcinoma (mRCC) as a treatment standard in the cytokine era. However, first-line systemic therapy for mRCC changed in 2005 with FDA approval of VEGFR TKIs. W